4 Reasons Life Science Companies Should Invest in a Virtual Data Room

With new technologies and discoveries advancing at a rapid pace, the life sciences sector is hotter than ever before. Biotech, pharmaceutical, and medical device companies need to make sure that their fundraising, innovation, and strategic partnership efforts are conducted smoothly and at maximum efficiency.

To share their sensitive financial documents and intellectual property data, many life science companies make use of a virtual data room: a secure online repository for storing and sharing private, confidential information with various parties.

In this article, we’ll discuss 4 reasons why virtual data rooms are an excellent investment for life science companies.

Read More

Virtual Data Rooms: Everything You Need to Know

As the name suggests, a virtual data room, or as it is more frequently called, a “VDR,” is an online database in which companies can store and share confidential information, usually used during a financial transaction. It may also be described as a type of electronic repository or document filing system. With the ubiquitous reliance on computers and specialized software to keep a business running smoothly, coupled with the fact that more and more companies are making the transition to a completely paperless office, many of the previously document-heavy operational practices have been shifted to the virtual realm.

Read More

Venture Capital Trends in Biotech

Last year, venture capital funding for the biotechnology sector reached record levels, which obviously caused the broader medical category to reach a new high as well. Even though many markets began to experience declines toward the end of last year and are continuing to witness these declines this year, it does not look like the same is true for biotechnology. Granted, there was a flurry of IPO activity in the early months of 2015 that likely will not repeat itself this year, but corporate venture capital and corporate equity investors appear poised to continue to bolster the surging biotech sphere. The following aspects of biotech seem particularly attractive to investors right now:

Read More

Commonly Missed Tax Breaks for Startups and Small Businesses

It is hard to believe, but it is already that time of year when companies have to start thinking about submitting tax returns. For many companies, this is one of the most dreaded times of the calendar year. There are plenty of do-it-yourself services that can guide you through the process, but it does not make it any less confusing. And, as your company grows, the complexity of doing your company’s taxes usually grows along with it. The following is by no means intended to be an exhaustive list of tax breaks for small businesses, and companies must research to ensure that they are entitled to any such deductions or credits, but here are a few that are frequently overlooked:

Read More

Webinar Recap: Raising Capital From Life Science Investors

On October 22, 2015, we hosted a valuable webinar with Life Science Nation (LSN) featuring Michael Quigley, Director of Research for LSN. During the webinar Michael discussed his views and experiences on raising capital in the life science space, as well as key best practices when seeking out and working with investors.

Read More

Insights into Using a SecureDocs Virtual Data Room from Inogen's CFO

Ali Bauerlein is Chief Financial Officer and Co-Founder of Inogen, Inc. A medical technology company that develops, manufactures and markets innovative oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. In the interview below Ali discusses why Inogen’s executive team chose to use a SecureDocs Virtual Data Room during their IPO, and how it continues to benefit their business today.


Read More

Raising Capital from Life Science Investors [WEBINAR]

DATE CHANGE: Webinar hosted by SecureDocs & Life Science Nation on October 22, 2015 at 10am PST. 


While the current IPO environment has created a much more positive outlook for life science and drawn significant capital from retail investors, there remains a very high level of competition from entrepreneurs for those dollars in the early stage. Being able to understand the current investor landscape and how to navigate it will dramatically increase your chances of getting in front of the right investors. 


Click here to watch "Raising Capital from Life Science Investors" now!



Here are four quick tips  for working with investors: 

Read More

Protecting Intellectual Property Crucial to Promoting Innovation in Life Sciences

Innovation is one of the most significant forces underpinning the growth of our economy. In the life science and technology industries, innovation is of paramount importance, perhaps even more so than in any other sector. However, advancements in these areas will be stalled if efforts are not made to promote and protect innovation, possibly causing catastrophic economic consequences. In recognition of this fact, there have been ongoing negotiations regarding various international trade agreements, such as the Trans-Pacific Partnership Agreement, that are seeking to include provisions that fortify, expand, and enforce international intellectual property (IP) agreements.

Read More

Why Biotech Startup Funding is on the Rise and Here to Stay

Biotech startup funding is better than you think, and funding growth could be here for the long term. No one can blame early stage biotech startups grumbling about the difficulties getting funded, especially when their challenges are contrasted with software startups.  Billion dollar valuations for software companies with no revenue have given way to deca billion dollar companies with no revenue.  Coupled with ongoing drumbeat of relentless cutting and restructuring R&  at almost all Big Pharma companies, it’s easy to wallow in a pessimistic swamp regarding early stage funding for life science startups, except for one thing:  Startup funding for Biotechs is blowing up.  Not only that, the long-term trend points to continued growth in early stage life science investment.  So what’s changed?

Read More

Life Science Funding Focused on Predictions and Preventions

Global investments in life science startups and other health care oriented companies have grown exponentially over the last few years. There are a somewhat surprising number of companies willing to fork over substantial sums of money because of their belief (or perhaps just incredibly optimistic expectation) that innovative approaches to detecting and preventing disease will ultimately yield generous returns. One extremely well known behemoth actually devoted upwards of one-third of its money to fund some of these pioneering endeavors. Obviously, there are a lot of companies (maybe even the vast majority of them) that cannot risk that kind of cash in an area that, generally speaking, is still considered relatively young and uncertain. But, for those companies that can afford or are willing to gamble a bit more, funding life science startups certainly seems like a more than decent bet.

Read More